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To the Editor: Cozollino and colleagues present a thoughtful
review on vascular calcification (VC) in chronic kidney
disease (CKD) and discuss the evidence supporting a
dominant role for disordered mineral metabolism in the
rapid progression of calcification seen in stage 5 CKD.1
However, the title and the article may lead one to conclude
that either VC is a major problem only in stage 5 CKD or that
disordered mineral metabolism plays a dominant role across
the entire spectrum of CKD. Accumulating evidence suggests
that VC is present in over 90% of diabetics (and is often quite
severe) and 40% of nondiabetics with CKD, long before stage
5 CKD or treatment with calcium-based phosphate binders,
and this appears to be unrelated to disordered mineral
metabolism.2,3 This observation is consistent with the
authors’ observations that phosphorus appears to induce
calcification only when its concentration in the culture media
exceeds 2.0 mmol/l – levels only rarely observed in stage 3 or 4
CKD. Finally, progression of VC is observed among diabetics
with CKD, over a rather short interval, long before stage 5
CKD, and this also appears to be independent of disordered
mineral metabolism.4
Thus, the available evidence suggests that VC begins and is
a significant problem early in CKD, and this is independent
of disordered mineral metabolism. Relatively rapid
progression of VC is demonstrable in nondialyzed diabetic
CKD, the process accelerates with worsening renal function
and disordered mineral metabolism likely assume a domi-
nant role quite late in the course of CKD (probably stage
4 or 5).
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